Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

365 ARTÍCULOS , VIENDO DEL 181 AL 195

The multifactorial nature of Alzheimer's disease and related therapeutic strategies

do Carmo Carreiras M, Marco-Contelles J.

Curr Pharm Des. 2010;16(25):2765. doi: 10.2174/138161210793176554.

Cell death targets and potential modulators in Alzheimer's disease

Castro RE, Santos MM, Glória PM, Ribeiro CJ, Ferreira DM, Xavier JM, Moreira R, Rodrigues CM.

Curr Pharm Des. 2010;16(25):2851-64. doi: 10.2174/138161210793176563.

Nitric oxide: target for therapeutic strategies in Alzheimer's disease

Fernandez AP, Pozo-Rodrigalvarez A, Serrano J, Martinez-Murillo R.

Curr Pharm Des. 2010;16(25):2837-50. doi: 10.2174/138161210793176590.

Neuroinflammation, oxidative stress and the pathogenesis of Alzheimer's disease

Agostinho P, Cunha RA, Oliveira C.

Curr Pharm Des. 2010;16(25):2766-78. doi: 10.2174/138161210793176572.

Glycogen synthase kinase-3 (GSK-3) inhibitors for the treatment of Alzheimer's disease

Medina M, Avila J.

Curr Pharm Des. 2010;16(25):2790-8. doi: 10.2174/138161210793176581.

Structural determinants of the multifunctional profile of dual binding site acetylcholinesterase inhibitors as anti-Alzheimer agents

Galdeano C, Viayna E, Arroyo P, Bidon-Chanal A, Blas JR, Muñoz-Torrero D, Luque FJ.

Curr Pharm Des. 2010;16(25):2818-36. doi: 10.2174/138161210793176536.

Inaccuracy in clinical trials: effects and methods to control inaccuracy

Kobak KA.

Curr Alzheimer Res. 2010 Nov;7(7):637-41. doi: 10.2174/156720510793499057.

Why so few drugs for Alzheimer's disease? Are methods failing drugs?

Becker RE, Greig NH.

Curr Alzheimer Res. 2010 Nov;7(7):642-51. doi: 10.2174/156720510793499075.

Cognitive stimulation therapy in the treatment of neuropsychiatric symptoms in Alzheimer's disease: a randomized controlled trial

Niu YX, Tan JP, Guan JQ, Zhang ZQ, Wang LN.

Clin Rehabil. 2010 Dec;24(12):1102-11. doi: 10.1177/0269215510376004. Epub 2010 Aug 16.

The role of tumor necrosis factor-alpha in cognitive improvement after peroxisome proliferator-activator receptor gamma agonist pioglitazone treatment in Alzheimer's disease

Hanyu H, Sato T, Sakurai H, Iwamoto T.

J Am Geriatr Soc. 2010 May;58(5):1000-1. doi: 10.1111/j.1532-5415.2010.02841.x.

The inhibitory effects of different curcuminoids on β-amyloid protein, β-amyloid precursor protein and β-site amyloid precursor protein cleaving enzyme 1 in swAPP HEK293 cells

Liu H, Li Z, Qiu D, Gu Q, Lei Q, Mao L.

Neurosci Lett. 2010 Nov 19;485(2):83-8. doi: 10.1016/j.neulet.2010.08.035. Epub 2010 Aug 18.

Introduction to the special issue on Alzheimer's disease

Pangalos MN, Randall AD.

Neuropharmacology. 2010 Sep-Oct;59(4-5):219-20. doi: 10.1016/j.neuropharm.2010.07.021.

Is BACE1 a suitable therapeutic target for the treatment of Alzheimer's disease? Current strategies and future directions

Klaver DW, Wilce MC, Cui H, Hung AC, Gasperini R, Foa L, Small DH.

Biol Chem. 2010 Aug;391(8):849-59. doi: 10.1515/BC.2010.089.

Rosiglitazone monotherapy in mild-to-moderate Alzheimer's disease: results from a randomized, double-blind, placebo-controlled phase III study

Gold M, Alderton C, Zvartau-Hind M, Egginton S, Saunders AM, Irizarry M, Craft S, Landreth G, Linnamägi U, Sawchak S.

Dement Geriatr Cogn Disord. 2010;30(2):131-46. doi: 10.1159/000318845. Epub 2010 Aug 21.

The development of new therapeutics for Alzheimer's disease

Carter MD, Simms GA, Weaver DF.

Clin Pharmacol Ther. 2010 Oct;88(4):475-86. doi: 10.1038/clpt.2010.165. Epub 2010 Sep 1.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias